Concord Drugs Limited has submitted its quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 to BSE Limited for the quarter ended March 31, 2026. The pharmaceutical company's Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, issued the compliance certificate confirming adherence to dematerialization requirements during the period from January 1, 2026 to March 31, 2026.

Quarterly Compliance Certificate Details

The certificate was submitted by S Manoj Kumar Reddy, Whole Time Director (DIN: 06991382), on April 10, 2026, ensuring proper corporate authorization through digital signature. Aarthi Consultants Private Limited, serving as the Category I Registrars & Share Transfer Agents with SEBI Registration Number INR000000379, issued the compliance certificate on April 3, 2026.

Dematerialization Compliance Actions

Aarthi Consultants Private Limited confirmed completion of all required actions within 15 days of receiving certificates from depository participants for dematerialization purposes. The compliance actions included ensuring securities are listed on appropriate stock exchanges, mutilating and cancelling physical certificates forwarded by participants, and substituting the depository name as registered owner in company records.

Corporate Information and Authorization

Concord Drugs Limited, incorporated under CIN L24230TG1995PLC020093, maintains its registered office and factory at Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, with administrative operations at L B Nagar, Hyderabad. The company trades under scrip code 538965 on BSE Limited.

The quarterly certificate submission demonstrates Concord Drugs Limited's continued compliance with SEBI depositories regulations, ensuring proper handling of dematerialization processes through its appointed registrar and share transfer agent for the quarter ended March 31, 2026.

Concord Drugs Limited has announced strong financial performance for the quarter ended December 31, 2025, demonstrating robust revenue growth and sustained profitability across both standalone and consolidated operations.

Financial Performance Overview

The company delivered impressive results for Q3FY26, with significant improvements in key financial metrics compared to the corresponding period last year.

Nine-Month Performance

For the nine months ended December 31, 2025, the company maintained strong momentum with substantial revenue growth and improved profitability.

Consolidated Results

The consolidated financial results showed similar positive trends, reflecting the overall strength of the company's operations:

• Total Revenue: ₹1,698.75 lakhs for Q3FY26
• Net Profit: ₹21.69 lakhs for the quarter
• Nine-month Revenue: ₹4,087.24 lakhs
• Nine-month Net Profit: ₹52.69 lakhs

Capital Structure and Equity

The company's financial position remained stable with a paid-up capital of ₹1,317.50 lakhs and other equity of ₹3,482.21 lakhs. The earnings per share for the nine-month period stood at ₹0.40 on both basic and diluted basis.

Board Approval and Compliance

The unaudited financial results were reviewed and recommended by the Audit Committee before being approved by the Board of Directors at their meeting held on February 14, 2026. The results have been filed with stock exchanges in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The detailed quarterly financial results are available on the company's website at www.concorddrugs.in and on the stock exchange website at www.bseindia.com .